Farxiga Manufacturer Bridge Programs: How to Get Dapagliflozin Cheaper in 2026

What Farxiga Actually Costs (and Why Bridge Programs Exist)

Farxiga's retail price sits around $620 for a 30-tablet supply at major U.S. Pharmacies in mid-2026. That figure reflects the list price before any insurance negotiation, rebate, or assistance program is applied. For the roughly 26.8 million Americans diagnosed with type 2 diabetes who lack adequate drug coverage, that cost is a significant barrier to consistent therapy. [1]

Dapagliflozin's clinical value is well-documented. The DECLARE-TIMI 58 trial (N=17,160) showed the drug reduced the composite of cardiovascular death or worsening heart failure by 17% compared with placebo in patients with type 2 diabetes and high cardiovascular risk (hazard ratio 0.83, 95% CI 0.73 to 0.95). [2] The DAPA-HF trial (N=4,744) demonstrated a 26% reduction in the composite of worsening heart failure or cardiovascular death in patients with heart failure with reduced ejection fraction, regardless of diabetes status (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001). [3] The DAPA-CKD trial (N=4,304) showed a 39% reduction in a composite renal or cardiovascular outcome in chronic kidney disease patients (hazard ratio 0.61, 95% CI 0.51 to 0.72, P<0.001). [4]

Given that evidence, major guidelines now recommend dapagliflozin across multiple indications. The 2024 American Diabetes Association Standards of Care classify SGLT2 inhibitors as preferred add-on agents in type 2 diabetes with established cardiovascular disease, heart failure, or CKD. [5] Interrupting therapy because of cost undermines outcomes that those trials proved are achievable. That is the core reason manufacturer bridge programs exist.

How Bridge Programs Fit Into the Broader Access Picture

"Bridge program" is industry shorthand for short-term free or deeply discounted drug supply intended to prevent a gap while insurance coverage, prior authorization, or a longer-term patient assistance application is pending. AstraZeneca uses the term broadly to include copay cards, free trial offers, and enrollment in its formal Patient Assistance Program (PAP), the AZ&Me Prescription Savings program.

Who Sets the Rules

The FDA regulates what AstraZeneca can print on labeling and promotional materials but does not govern assistance program eligibility directly. [6] Program terms are set by AstraZeneca and can change without notice. The income thresholds, copay caps, and free-trial durations described here reflect program terms as of July 2026. Verify current terms at the AstraZeneca savings portal or call 1-800-AZandMe before submitting any application.

The AstraZeneca Farxiga Savings Card (Commercially Insured Patients)

The savings card is the fastest option for patients who have commercial (private) insurance. Eligible patients can pay as little as $0 per month, subject to a program maximum benefit per calendar year. The card works like a secondary coupon applied at the pharmacy counter after your insurer processes the claim.

Eligibility Requirements

To qualify for the Farxiga savings card you must meet all of the following:

• Have a valid prescription for Farxiga (dapagliflozin 5 mg or 10 mg)
• Be covered by a commercial insurance plan (employer-sponsored, marketplace, or individual)
• Not be enrolled in any federal or state government health insurance program, including Medicare Part D, Medicaid, TRICARE, or VA coverage
• Be a U.S. Resident

There is no income cap for the commercial savings card. AstraZeneca applies a per-fill or annual benefit cap; the specific dollar figure is listed in the program terms and has historically ranged from $1,500 to $3,600 per calendar year. Once you hit that cap, out-of-pocket costs revert to your normal plan cost-sharing until January 1.

How to Enroll and Use It

1. Download or print the savings card from the AstraZeneca Farxiga savings page or ask your prescriber's office for a card.
2. Register online or by phone to activate the card (some versions auto-activate at first fill).
3. Present the card alongside your insurance card at any participating retail or mail-order pharmacy.
4. The savings are applied automatically at the point of sale.

The ADA's 2024 Standards of Care explicitly acknowledge cost as a driver of non-adherence and recommend that clinicians proactively connect patients with manufacturer savings programs. [5] A 2022 analysis published in JAMA Network Open found that patients who received cost-sharing assistance for SGLT2 inhibitors had significantly higher 12-month medication adherence (proportion of days covered 0.78 vs. 0.61, P<0.001) compared with those who paid full cost-sharing. [7]

What to Do If Your Pharmacy Rejects the Card

Rejections happen when a pharmacy's system does not recognize the BIN/PCN/Group numbers on the card, or when the fill is processed as a government-payer claim in error. Ask the pharmacist to run the card as a secondary claim using the BIN 004682 (verify current BIN on the card itself). If the rejection persists, call the savings program helpline printed on the back of the card.

AZ&Me Prescription Savings: The Free-Drug PAP for Uninsured and Underinsured Patients

Patients without insurance, or whose insurance does not cover Farxiga at all, may qualify for AZ&Me, AstraZeneca's formal Patient Assistance Program. Approved participants receive Farxiga at no cost, shipped directly to their home or prescriber's office.

Income Eligibility

As of mid-2026, AZ&Me uses a household income threshold of at or below approximately 600% of the federal poverty level (FPL). For a single-person household, 600% FPL equals roughly $90,480 per year based on 2026 HHS poverty guidelines. [8] Four-person households qualify at approximately $186,120. AstraZeneca reserves the right to adjust these thresholds annually.

Required Documents

• Completed AZ&Me application form (download at azandme.com or 1-800-AZandMe)
• Signed prescription from a licensed U.S. Prescriber
• Proof of income: most recent federal tax return, pay stubs, or a Social Security award letter
• Proof of insurance status (or attestation of no coverage)

Processing Timeline

Standard applications take 2 to 4 weeks from the date AstraZeneca receives a complete file. Expedited review is available for patients with documented urgent clinical need; ask the prescriber to note urgency in a cover letter. During the wait, ask your prescriber to request a 30-day free trial supply (see below) to avoid a gap.

Annual Renewal

AZ&Me enrollment is not permanent. Most approvals are valid for 12 months and require re-certification. Set a calendar reminder 60 days before the expiration date on your approval letter. Missing renewal leaves a supply gap.

The 30-Day Free Trial Offer

AstraZeneca has historically offered a one-time 30-day free supply to patients who are new to Farxiga. This offer is separate from the savings card and AZ&Me. It is intended for patients who want to confirm insurance coverage or prior-authorization status before committing to ongoing therapy.

The free trial is generally available through the AstraZeneca savings portal or through participating prescriber offices. It cannot be combined with the savings card in the same transaction, and it cannot be used a second time for the same patient.

The HealthRX Access Decision Framework for dapagliflozin routes patients as follows:

1. Commercially insured, Farxiga covered on formulary: Use the savings card to minimize copay.
2. Commercially insured, Farxiga not covered or requires step therapy: Use the 30-day free trial while the prescriber submits a prior authorization or formulary exception. Simultaneously enroll in the savings card in case the PA is approved quickly.
3. Uninsured or underinsured, income at or below 600% FPL: Apply to AZ&Me PAP; request 30-day trial to bridge the 2 to 4 week processing window.
4. Uninsured, income above 600% FPL: Evaluate GoodRx or similar discount programs at cash-pay pharmacies; consider requesting a generic SGLT2 inhibitor (dapagliflozin generics entered the U.S. Market in late 2025 after Farxiga's core patent expiration).
5. Medicare Part D enrolled: AZ&Me PAP is the only manufacturer option; also evaluate the Medicare Extra Help (Low Income Subsidy) program through SSA.gov.
6. Medicaid enrolled: Most state Medicaid programs cover dapagliflozin; if coverage is denied, request a Medicaid prior authorization appeal with clinical documentation citing DAPA-HF and DAPA-CKD outcome data. [3][4]

Medicare and Medicaid: Special Rules

Federal anti-kickback statutes prohibit manufacturers from offering copay assistance to patients enrolled in Medicare or Medicaid. [9] This is not an arbitrary policy restriction. The Office of Inspector General has issued multiple advisory opinions confirming that copay card use by federal beneficiaries constitutes an improper inducement. [9] Violating this rule can expose pharmacies and prescribers to legal liability.

What Medicare Part D Patients Can Do

Medicare Part D beneficiaries have three legitimate routes to lower dapagliflozin costs:

• AZ&Me PAP: Income-qualified beneficiaries can receive drug at no cost through AZ&Me, which operates outside the Part D benefit.
• Medicare Extra Help (Low Income Subsidy): The Social Security Administration's Extra Help program caps monthly drug costs for qualifying low-income Medicare beneficiaries. In 2026, full Extra Help beneficiaries pay no more than $4.50 per generic fill and $11.20 per brand fill. [10] Applications are accepted at SSA.gov or through a local State Health Insurance Assistance Program (SHIP) counselor.
• Medicare Inflation Reduction Act Negotiated Price: The Inflation Reduction Act authorized CMS to negotiate Part D drug prices directly with manufacturers beginning in 2026 for select high-cost drugs. Dapagliflozin was included in the first negotiation cycle; the negotiated price takes effect for Medicare beneficiaries beginning in January 2026. Confirm the current negotiated price with your Part D plan.

What Medicaid Patients Can Do

Medicaid coverage of dapagliflozin varies by state formulary. If your state Medicaid plan requires a prior authorization or step therapy through metformin first, your prescriber can submit clinical documentation citing the ADA guideline recommendation for SGLT2 inhibitors in patients with CKD or heart failure as a preferred therapy independent of HbA1c. [5]

Prior Authorization and Formulary Exceptions: Clearing the Insurance Hurdle

Even with a savings card available, many commercial plans require prior authorization before they cover Farxiga. A denied PA is often the trigger that prompts patients to seek manufacturer assistance in the first place.

What Supports a PA Approval

According to the 2023 ACC/AHA Heart Failure Guideline, SGLT2 inhibitors (specifically dapagliflozin and empagliflozin) carry a Class I, Level of Evidence A recommendation for patients with heart failure with mildly reduced or preserved ejection fraction. [11] Submitting that guideline text with a PA request, alongside the patient's documented HFrEF or CKD diagnosis and an eGFR reading, substantially strengthens the case.

The DAPA-CKD trial showed benefit beginning at eGFR as low as 25 mL/min/1.73m², and the FDA approved Farxiga for CKD in patients with eGFR <45 mL/min/1.73m² who are at risk of progression. [4][12] Insurers who see that FDA-approved indication language alongside a matching diagnosis code are less likely to sustain a denial.

Formulary Exception vs. PA

A formulary exception requests placement of a non-formulary drug on the patient's benefit. A prior authorization request asks for coverage approval for a formulary or non-formulary drug subject to utilization management. Some plans require both steps. Your prescriber's office (or a specialty pharmacy that handles hub services) can submit both simultaneously to save time.

Generic Dapagliflozin: A 2025-2026 Development That Changes the Cost Picture

Dapagliflozin's primary U.S. Patent expired in late 2025, and the FDA approved the first generic dapagliflozin products shortly after. [13] Generic entry typically reduces retail prices by 70 to 90% within 12 to 18 months of launch, based on historical IQVIA data on other oral diabetes drugs. [14]

What Generic Entry Means Practically

• Patients without insurance should ask for generic dapagliflozin 10 mg at cash-pay pharmacies. GoodRx and similar discount programs already list generic pricing in many markets.
• Commercially insured patients on formularies with a generic tier will likely face lower copays for generic dapagliflozin than for branded Farxiga, depending on plan design.
• AZ&Me and the Farxiga savings card apply only to branded Farxiga, not to generics. Generic discount programs (GoodRx, RxSaver, Cost Plus Drugs) are the better route for generic dapagliflozin.

The FDA maintains a current list of approved dapagliflozin products (both branded and generic) in its Orange Book. [13] Checking the Orange Book before filling a prescription confirms which generics have an AB therapeutic equivalence rating, meaning they are substitutable for Farxiga at the pharmacy.

HSA and FSA Eligibility for Farxiga

Farxiga qualifies as an eligible medical expense under both Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) because it is a prescription drug. IRS Publication 502 defines qualified medical expenses to include prescription medications. [15] There is no special documentation requirement beyond a valid prescription; your standard pharmacy receipt serves as the FSA/HSA reimbursement record.

Using HSA or FSA dollars reduces the effective after-tax cost of Farxiga by your marginal income tax rate. For a patient in the 22% federal bracket, a $620 list-price fill costs the equivalent of roughly $484 in pre-tax dollars when paid from an HSA.

HSA and FSA dollars can be stacked with manufacturer savings programs. If your savings card brings your copay to $40, you may pay that $40 from your HSA or FSA and still claim the tax benefit on that out-of-pocket amount.

Specialty Pharmacy, Hub Services, and Prescriber Office Support

Some prescriber offices, particularly cardiology and nephrology practices that see high volumes of patients on SGLT2 inhibitors, maintain relationships with specialty pharmacies that offer dedicated hub services for AstraZeneca products. Hub services include benefits investigation, PA submission, and enrollment assistance for AZ&Me, all handled by the specialty pharmacy's access team rather than the patient.

Ask your cardiologist, nephrologist, or endocrinologist whether their office has an AstraZeneca field reimbursement manager (FRM) contact. FRMs can expedite savings card enrollments and escalate stalled PA cases directly with payers.

The CREDENCE trial (N=4,401), while conducted with canagliflozin, confirmed the class-level renal protection of SGLT2 inhibitors and helped establish the nephrology prescribing patterns that now drive hub-service infrastructure for all drugs in the class. [16] Nephrologists are now among the highest-volume prescribers of dapagliflozin, and their offices are often the most familiar with the access support system.

Comparing the Programs Side by Side

| Program | Who Qualifies | Cost to Patient | Processing Time | |---|---|---|---| | Farxiga Savings Card | Commercially insured, no government coverage | $0/month (up to annual cap) | Instant at pharmacy | | 30-Day Free Trial | New Farxiga patients, any insurance status | $0 for one fill | Same-day or next-day | | AZ&Me PAP | Uninsured/underinsured, income <600% FPL | $0 ongoing | 2 to 4 weeks | | Medicare Extra Help | Medicare Part D, low income | $4.50, $11.20/fill | 2 to 6 weeks (SSA) | | Generic dapagliflozin (GoodRx) | Any patient (no income/insurance restriction) | ~$50, $80/month (estimates; check current pricing) | Instant at pharmacy | | HSA/FSA payment | HSA/FSA account holder with valid Rx | Pre-tax dollars reduce effective cost | Instant |

Clinical Reminder: Do Not Stop Dapagliflozin Without Medical Guidance

Cost-driven self-discontinuation of dapagliflozin carries real clinical risk. In the DAPA-HF trial, the separation of Kaplan-Meier curves for the primary endpoint began within 28 days of randomization, and the benefit was sustained through the entire 18.2-month median follow-up. [3] Patients with heart failure who abruptly stop an SGLT2 inhibitor pending insurance resolution should contact their prescriber for a bridge strategy rather than simply skipping doses.

The 2024 ADA Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit is recommended as part of the glucose-lowering regimen independent of HbA1c or individualized HbA1c target." [5] That recommendation holds regardless of whether the patient is waiting on a prior authorization decision.

If no bridge option resolves within 72 hours and the patient has HFrEF or stage 3 to 4 CKD, the prescriber should document medical necessity for an emergency or expedited PA, noting the Class I, Level A guideline recommendation from the 2023 ACC/AHA Heart Failure Guideline. [11] Most commercial payers have a 72-hour turnaround obligation for urgent PA requests under state prompt-pay regulations.